DGX vs CRL — Key Metrics
| Metric | DGX (QUEST DIAGNOSTICS INC) | CRL (CHARLES RIVER LABORATORIES INTERNATIONAL INC) |
|---|---|---|
| Price | 259.69 | 333.25 |
| Market Cap | 28.57 Billion | 15.97 Billion |
| P/E (TTM) | 25.51 | 311.45 |
| P/B (Quarterly) | 3.487 | 4.845 |
| P/S (TTM) | 2.41 | 4.02 |
| Net Profit Margin (TTM) | 9.5 | 1.0 |
| Gross Margin (TTM) | 33.1 | 33.3 |
| ROE (TTM) | 15.2 | 1.3 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Underperform
Greatly Underperform
Recommendation Summary
Stock DGX is projected to underperform the market, stock CRL is projected to greatly underperform the market. Upfront Recommendation: DGX.
Financial Metrics
| DGX | Metrics | CRL |
|---|---|---|
| $259.69 | Price | $333.25 |
| — | Market Capitalization | — |
| 25.51 | Price to Earnings Ratio | 311.45 |
| 2.41 | Price to Sales | 4.02 |
| 20.78 | Price to FCF Ratio | 39.96 |
| 7.29 | Price to Gross Profit | 12.05 |
| 9.17 | Price to Current Assets | 10.4 |
DGX vs CRL at a glance
Quest Diagnostics INC (DGX) and Charles River Laboratories International INC (CRL) are both Diagnostics & Research companies in the Healthcare sector. DGX is the larger, at $28.6 billion in market value against $16.0 billion for CRL, about 1.8 times the size.
On trailing-twelve-month figures, DGX trades at 25.5 times trailing earnings and CRL at 311.4; net profit margins are 9.5% and 1.0%.
The Upfront Investment model currently rates DGX Underperform and CRL Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.